Edition:
India

Novacyt SA (ALNOV.PA)

ALNOV.PA on Paris Stock Exchange

0.08EUR
2:05pm IST
Change (% chg)

€-0.00 (-0.53%)
Prev Close
€0.08
Open
€0.08
Day's High
€0.08
Day's Low
€0.07
Volume
96,505
Avg. Vol
857,285
52-wk High
€0.53
52-wk Low
€0.06

Latest Key Developments (Source: Significant Developments)

Novacyt Issues Tranche Of New Ordinary Shares Of EUR 1/15 Each To Negma Group Limited
Tuesday, 27 Aug 2019 

Aug 27 (Reuters) - NOVACYT SA ::ISSUES TRANCHE OF NEW ORDINARY SHARES OF €1/15 EACH TO NEGMA GROUP LIMITED FOLLOWING THE RECEIPT OF CONVERSION NOTICES.ADMISSION OF NEW ORDINARY SHARES TO TRADING ON EURONEXT IS EXPECTED TO OCCUR ON OR BEFORE 30 AUGUST 2019..NUMBER OF NOTES CONVERTED: 40.CONVERSION AMOUNT: €100,000.APPLICATION WILL BE MADE FOR 1,500,000 NEW ORDINARY SHARES TO BE ADMITTED TO TRADING ON AIM.  Full Article

Novacyt H1 Revenues Up 12% At 7.2 Million Euros
Tuesday, 30 Jul 2019 

July 30 (Reuters) - NOVACYT SA ::NOVACYT S.A.: HALF-YEAR TRADING UPDATE.REVENUES FOR FIRST HALF OF 2019 WERE EUR 7.2M COMPARED TO RESTATED REVENUES FOR 2018 OF EUR 6.4M.THE PERFORMANCE OF THE PRIMERDESIGN AND LAB21 BUSINESSES REMAINS STRONG ENTERING THE SECOND HALF OF THE YEAR.EXPECTS TO SHOW INCREASED ADJUSTED EBITDA PROFITABILITY FOR FULL YEAR COMPARED TO 2018.BOTH COMPANIES HAVE SIGNIFICANT SALES PIPELINES AND EXPECT SALES TO BE HIGHER THAN H1.  Full Article

Novacyt Has Completed The Sale Of Its Clinical Laboratory Business
Thursday, 18 Jul 2019 

July 18 (Reuters) - NOVACYT SA ::HAS COMPLETED SALE OF ITS CLINICAL LABORATORY BUSINESS TO CAMBRIDGE PATHOLOGY BV.SALE WILL ENABLE NOVACYT TO FOCUS MORE CLOSELY ON EXPANSION AND VALUE OF ITS CORE BUSINESSES, PRIMERDESIGN AND LAB21.COMPANY IS RECEIVING £100,000 IN CASH ON COMPLETION.£100,000 OF THE REMAINING £300,000 OF CASH WILL BE RECEIVED ON 1 SEPTEMBER 2019 (" RETENTION").THREE INSTALMENTS OF £66,667 ON FIRST, SECOND AND THIRD ANNIVERSARY OF COMPLETION OF SALE (" DEFERRED PAYMENTS") WILL BE RECEIVED OF THE REMAINING £300,000 OF CASH.  Full Article

Novacyt Enters 5 Million Euro Convertible Bonds Funding Programme
Tuesday, 23 Apr 2019 

April 23 (Reuters) - NOVACYT SA ::NOVACYT S.A.: CONVERTIBLE BOND FACILITY.HAS ENTERED INTO A CONVERTIBLE BONDS WITH WARRANTS FUNDING PROGRAMME ("AGREEMENT"), FOR UP TO EUR 5.0 MILLION (NET OF EXPENSES) WITH PARK PARTNERS GP AND NEGMA GROUP LTD.INITIAL TRANCHE OF EUR 2.0 MILLION.REMAINING EUR 3.0 MILLION OF CONVERTIBLE BONDS CAN BE ISSUED BY COMPANY OVER NEXT 36 MONTHS FOLLOWING TODAY'S CLOSING OF AGREEMENT.FOLLOWED BY SIX FURTHER TRANCHES, EACH OF AN AGGREGATE NOMINAL VALUE OF EUR 500,000.REMAINING EUR 3.0 MILLION OF CONVERTIBLE BONDS CAN BE ISSUED BY COMPANY OVER NEXT 36 MONTHS FOLLOWING TODAY'S CLOSING OF AGREEMENT..INITIAL EUR 2.0M OF FUNDING, WILL BE USED PRIMARILY FOR GENERAL WORKING CAPITAL PURPOSES AND SUPPORT PLANNED GROWTH OF BUSINESS IN SHORT AND MEDIUM TERM.  Full Article

Novacyt Expands Development Partnership With Immunexpress
Monday, 8 Apr 2019 

April 8 (Reuters) - NOVACYT SA ::NOVACYT EXPANDS DEVELOPMENT PARTNERSHIP WITH IMMUNEXPRESS.EXTENSION OF CONTRACT CONTINUES MULTI-YEAR ASSAY DESIGN AND DEVELOPMENT PROGRAM.  Full Article

Novacyt Updates On Debt Consolidation
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Novacyt SA ::NOVACYT S.A. - FUNDING UPDATE.COMPANY'S CASH POSITION AS AT 22 FEBRUARY 2019 WAS APPROXIMATELY EUR 950,000.IN ADVANCED DISCUSSIONS WITH DEBT PROVIDERS IN RELATION TO A MATERIAL INVESTMENT.INVESTMENT OF WHICH A SIGNIFICANT PROPORTION WILL BE USED TO CONSOLIDATE CO'S CURRENT DEBT OBLIGATIONS.EXPECTS TO COMPLETE THIS FINANCING WITHIN THE NEXT SIX TO EIGHT WEEKS.  Full Article

Novacyt Expects To Achieve Increased EBITDA Profitability In 2019
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - NOVACYT SA ::NOVACYT REVENUES FULL YEAR 2018.NOVACYT CONFIRMS THAT YEAR END REVENUES FROM CONTINUING OPERATIONS WILL BE APPROXIMATELY EUR 13.7M.COMPANY'S YEAR-END CASH BALANCE WAS APPROXIMATELY EUR 1.1M..CURRENT LAUNCH OF NEW MOLECULAR CE MARK ASSAYS BKV AND EBV ARE ALSO EXPECTED TO DRIVE INCREMENTAL GROWTH IN 2019..CO EXPECTS THAT, ON A CONTINUING OPERATIONS BASIS, WILL ACHIEVE INCREASED EBITDA PROFITABILITY IN 2019.  Full Article

Novacyt Estimates 2018 Revenue From Continuing Operations Of 13.7 Million Euros To 14.4 Million Euros
Monday, 24 Dec 2018 

Dec 24 (Reuters) - NOVACYT SA ::NOVACYT TRADING UPDATE.FOR 2018 ESTIMATES REVENUE FROM CONTINUING OPERATIONS, OF EUR 13.7M TO EUR 14.4M.GROSS AND EBITDA MARGINS FOR BOTH PRIMERDESIGN AND LAB21 ARE EXPECTED TO IMPROVE IN 2018, VERSUS 2017.THE EBITDA (EXCLUDING NOVAPREP®) FOR THE GROUP IS EXPECTED TO BE POSITIVE FOR THE FULL YEAR.CONFIRMS THAT NOVAPREP® WILL BE TREATED AS A DISCONTINUED OPERATION UNDER IFRS IN 2018 FULL YEAR RESULTS..CASH AT END OF YEAR IS EXPECTED TO BE BETWEEN €0.8M AND €1.0M AND ANY CASH FROM FUTURE SALE OF NOVAPREP® BUSINESS UNIT, AS WELL AS COMPANY’S CLINICAL LABORATORY UNIT WILL BE ADDITIVE.FULL INTEGRATION OF ACQUISITION OF PROFITABLE OMEGA INFECTIOUS DISEASE ASSETS ARE ALSO EXPECTED TO BE REALISED IN 2019, WHICH IS ANTICIPATED TO ADD ABOUT €2.5M OF REVENUE AND STRONG EBITDA.  Full Article

Novacyt Receives Order For Q16 Molecular Instruments
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - NOVACYT SA ::NOVACYT: COMPLETION OF SUBSTANTIAL Q16 MOLECULAR DIAGNOSTICS ORDER.EXPANDS CLINICAL DIAGNOSTIC REACH IN FAST GROWING CHINESE MARKET.PRIMERDESIGN HAS NOW SOLD OVER 450 Q16 UNITS SINCE ITS LAUNCH IN 2015.ORDER FOR 100 MOLECULAR DIAGNOSTIC INSTRUMENTS HAS BEEN PAID IN ADVANCE AND TAKES NUMBER OF Q16 INSTRUMENTS SOLD INTO ASIA PACIFIC REGION TO OVER 230 UNITS.THIS NEW CUSTOMER PROVIDES NOVACYT WITH A POTENTIAL OPPORTUNITY FOR FURTHER SIGNIFICANT INSTRUMENT, AND GENESIG® REAGENT SALES IN 2019.  Full Article

Novacyt H1 EBITDA Loss Stable at 0.5 Million Euros
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - NOVACYT SA ::NOVACYT PUBLISHES HALF YEAR 2018 RESULTS.H1 NET LOSS EUR 1.8 MILLION VERSUS LOSS OF EUR 1.7 MILLION YEAR AGO.H1 EBITDA LOSS EUR 0.5 MILLION VERSUS LOSS OF EUR 0.5 MILLION YEAR AGO."WE REMAIN COMMITTED TO BECOMING EBITDA PROFITABLE IN 2018."-CEO.H1 REVENUE EUR 7.0 MILLION VERSUS EUR 7.0 MILLION YEAR AGO." STRATEGIC REVIEW OF NOVAPREP IS ONGOING AND I EXPECT TO UPDATE MARKET ONCE IT HAS BEEN CONCLUDED."-CEO.  Full Article